Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients

Michel Jadoul, Brian A. Bieber, Paul Martin, Takashi Akiba, Chizoba Nwankwo, Jean Marie Arduino, David A. Goodkin, Ronald L. Pisoni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatitis C virus (HCV) infection is common in dialysis patients and is associated with increased morbidity and mortality. We used the Dialysis Outcomes and Practice Patterns Study (DOPPS, 1996–2015) to assess trends in the prevalence, incidence, and risk factors for HCV infection as defined by a documented diagnosis or antibody positivity. Among prevalent hemodialysis patients, HCV prevalence was nearly 10% in 2012–2015. Prevalence ranged from 4% in Belgium to as high as 20% in the Middle East, with intermediate prevalence in China, Japan, Italy, Spain, and Russia. HCV prevalence decreased over time in most countries participating in more than one phase of DOPPS, and prevalence was around 5% among patients who had recently (<4 months) initiated dialysis. The incidence of HCV infection decreased from 2.9 to 1.2 per 100 patient-years in countries participating in the initial phase of DOPPS. Although most units reported no seroconversions, 10% of units experienced 3 or more cases over a median of 1.1 years. High HCV prevalence in the hemodialysis unit was a powerful facility-level risk factor for seroconversion, but the use of isolation stations for HCV-positive patients was not associated with significantly lower seroconversion rates. Overall, despite a trend toward lower HCV prevalence among hemodialysis patients, the prevalence of HCV infection remains higher than in the general population. Combined with a high prevalence of HCV infection among patients with Stage 5 CKD, high rates of HCV seroconversion in a subset of hemodialysis units may contribute to this disparity.

Original languageEnglish (US)
Pages (from-to)939-947
Number of pages9
JournalKidney international
Volume95
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Virus Diseases
Hepacivirus
Renal Dialysis
Incidence
Dialysis
Middle East
Russia
Belgium
Spain
Italy
China
Japan
Morbidity

Keywords

  • chronic kidney disease
  • hemodialysis
  • hepatitis C virus

ASJC Scopus subject areas

  • Nephrology

Cite this

Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. / Jadoul, Michel; Bieber, Brian A.; Martin, Paul; Akiba, Takashi; Nwankwo, Chizoba; Arduino, Jean Marie; Goodkin, David A.; Pisoni, Ronald L.

In: Kidney international, Vol. 95, No. 4, 01.04.2019, p. 939-947.

Research output: Contribution to journalArticle

Jadoul, M, Bieber, BA, Martin, P, Akiba, T, Nwankwo, C, Arduino, JM, Goodkin, DA & Pisoni, RL 2019, 'Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients', Kidney international, vol. 95, no. 4, pp. 939-947. https://doi.org/10.1016/j.kint.2018.11.038
Jadoul, Michel ; Bieber, Brian A. ; Martin, Paul ; Akiba, Takashi ; Nwankwo, Chizoba ; Arduino, Jean Marie ; Goodkin, David A. ; Pisoni, Ronald L. / Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. In: Kidney international. 2019 ; Vol. 95, No. 4. pp. 939-947.
@article{338f38dd1fa94856abbbbbd4447117ca,
title = "Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients",
abstract = "Hepatitis C virus (HCV) infection is common in dialysis patients and is associated with increased morbidity and mortality. We used the Dialysis Outcomes and Practice Patterns Study (DOPPS, 1996–2015) to assess trends in the prevalence, incidence, and risk factors for HCV infection as defined by a documented diagnosis or antibody positivity. Among prevalent hemodialysis patients, HCV prevalence was nearly 10{\%} in 2012–2015. Prevalence ranged from 4{\%} in Belgium to as high as 20{\%} in the Middle East, with intermediate prevalence in China, Japan, Italy, Spain, and Russia. HCV prevalence decreased over time in most countries participating in more than one phase of DOPPS, and prevalence was around 5{\%} among patients who had recently (<4 months) initiated dialysis. The incidence of HCV infection decreased from 2.9 to 1.2 per 100 patient-years in countries participating in the initial phase of DOPPS. Although most units reported no seroconversions, 10{\%} of units experienced 3 or more cases over a median of 1.1 years. High HCV prevalence in the hemodialysis unit was a powerful facility-level risk factor for seroconversion, but the use of isolation stations for HCV-positive patients was not associated with significantly lower seroconversion rates. Overall, despite a trend toward lower HCV prevalence among hemodialysis patients, the prevalence of HCV infection remains higher than in the general population. Combined with a high prevalence of HCV infection among patients with Stage 5 CKD, high rates of HCV seroconversion in a subset of hemodialysis units may contribute to this disparity.",
keywords = "chronic kidney disease, hemodialysis, hepatitis C virus",
author = "Michel Jadoul and Bieber, {Brian A.} and Paul Martin and Takashi Akiba and Chizoba Nwankwo and Arduino, {Jean Marie} and Goodkin, {David A.} and Pisoni, {Ronald L.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.kint.2018.11.038",
language = "English (US)",
volume = "95",
pages = "939--947",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients

AU - Jadoul, Michel

AU - Bieber, Brian A.

AU - Martin, Paul

AU - Akiba, Takashi

AU - Nwankwo, Chizoba

AU - Arduino, Jean Marie

AU - Goodkin, David A.

AU - Pisoni, Ronald L.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Hepatitis C virus (HCV) infection is common in dialysis patients and is associated with increased morbidity and mortality. We used the Dialysis Outcomes and Practice Patterns Study (DOPPS, 1996–2015) to assess trends in the prevalence, incidence, and risk factors for HCV infection as defined by a documented diagnosis or antibody positivity. Among prevalent hemodialysis patients, HCV prevalence was nearly 10% in 2012–2015. Prevalence ranged from 4% in Belgium to as high as 20% in the Middle East, with intermediate prevalence in China, Japan, Italy, Spain, and Russia. HCV prevalence decreased over time in most countries participating in more than one phase of DOPPS, and prevalence was around 5% among patients who had recently (<4 months) initiated dialysis. The incidence of HCV infection decreased from 2.9 to 1.2 per 100 patient-years in countries participating in the initial phase of DOPPS. Although most units reported no seroconversions, 10% of units experienced 3 or more cases over a median of 1.1 years. High HCV prevalence in the hemodialysis unit was a powerful facility-level risk factor for seroconversion, but the use of isolation stations for HCV-positive patients was not associated with significantly lower seroconversion rates. Overall, despite a trend toward lower HCV prevalence among hemodialysis patients, the prevalence of HCV infection remains higher than in the general population. Combined with a high prevalence of HCV infection among patients with Stage 5 CKD, high rates of HCV seroconversion in a subset of hemodialysis units may contribute to this disparity.

AB - Hepatitis C virus (HCV) infection is common in dialysis patients and is associated with increased morbidity and mortality. We used the Dialysis Outcomes and Practice Patterns Study (DOPPS, 1996–2015) to assess trends in the prevalence, incidence, and risk factors for HCV infection as defined by a documented diagnosis or antibody positivity. Among prevalent hemodialysis patients, HCV prevalence was nearly 10% in 2012–2015. Prevalence ranged from 4% in Belgium to as high as 20% in the Middle East, with intermediate prevalence in China, Japan, Italy, Spain, and Russia. HCV prevalence decreased over time in most countries participating in more than one phase of DOPPS, and prevalence was around 5% among patients who had recently (<4 months) initiated dialysis. The incidence of HCV infection decreased from 2.9 to 1.2 per 100 patient-years in countries participating in the initial phase of DOPPS. Although most units reported no seroconversions, 10% of units experienced 3 or more cases over a median of 1.1 years. High HCV prevalence in the hemodialysis unit was a powerful facility-level risk factor for seroconversion, but the use of isolation stations for HCV-positive patients was not associated with significantly lower seroconversion rates. Overall, despite a trend toward lower HCV prevalence among hemodialysis patients, the prevalence of HCV infection remains higher than in the general population. Combined with a high prevalence of HCV infection among patients with Stage 5 CKD, high rates of HCV seroconversion in a subset of hemodialysis units may contribute to this disparity.

KW - chronic kidney disease

KW - hemodialysis

KW - hepatitis C virus

UR - http://www.scopus.com/inward/record.url?scp=85062811690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062811690&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2018.11.038

DO - 10.1016/j.kint.2018.11.038

M3 - Article

VL - 95

SP - 939

EP - 947

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -